Ultime notizie per Cdon (OTC:CDOAF) Azioni

Cdon AB is a Nordic region-based marketplace. Customers can choose to shop and compare prices on millions of products. Over 1,500 retailers offer their range on CDON's marketplace to increase their sales. This gives CDON various products, movies, music, computers, games, office supplies, books, toys, consumer electronics, household appliances, sports, outdoor, beauty care, fashion, shoes, computers, and computer products. Its geographical revenue comes from the majority of Sweden.

Li Auto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) shares gave up their earlier gains on Tuesday following the official launch of its new six-seat battery electric vehicle (BEV) family SUV, the Li i8.
Despite marking a significant expansion of the company&#8217;s EV portfolio and showcasing advanced technology, the announcement failed to sustain the stock&#8217;s recent upward momentum.
The company announced that it had officially launched the Li i8, a six-seat battery electric family SUV that redefines family mobility by blending off-road capability, sedan-like handling, and MPV-level comfort.
Also Read: <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/07/46413630/chinese-stocks-see-broad-rally-as-us-eases-chip-curbs" rel="noreferrer noopener">Chinese Stocks See Broad Rally As US Eases Chip Curbs</a>
This marks a bold expansion of the company&#8217;s EV lineup, with deliveries set to begin on August 20, 2025. Built on Li Auto&#8217;s new high-voltage BEV platform, the Li i8 features an in-house electric drive system, 5C supercharging battery packs with up to 720 km CLTC range, and access to the largest supercharging network among Chinese automakers.
The SUV supports ultra-fast charging, adding 500 km in just 10 minutes. Li Auto engineered the Li i8 with advanced safety systems, including multi-path energy absorption structures, LiDAR sensors, and AES technology.
All trims also feature high-level assisted driving systems, Li AD Pro and Li AD Max, powered by Horizon Robotics and Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) chips. The Max trim will also debut Li Auto&#8217;s proprietary VLA driver model with AI-powered reasoning and memory.
Inside, the Li i8 delivers a smart, spacious, yacht-inspired cabin equipped with the intelligent Li Xiang Tong Xue Agent. Powered by MindGPT, the agent can operate nearly all vehicle functions, execute complex tasks like scanning QR codes or food pickups, and adapt to individual users with Face ID and personalized memory.
Li Auto also announced a brand upgrade, pledging to create high-quality, private in-car spaces for families.
However, the excitement surrounding the new model contrasts with a slowdown in the <a target="_blank" href="https://www.benzinga.com/markets/tech/25/07/46190208/li-autos-strong-q2-deliveries-mask-junes-steep-decline" rel="noreferrer noopener">company&#8217;s overall performance</a>. Li Auto reported a year-over-year decline in June 2025 deliveries, which totaled 36,279 units, a 24.1% decrease amid intensifying competition in China&#8217;s electric vehicle market. Despite this, the company managed to surpass its revised second-quarter guidance, delivering 111,074 vehicles, a modest 2.4% increase from the same period last year.
Li Auto had lowered its second-quarter forecast in late June, citing temporary disruptions caused by sales system upgrades. Nonetheless, it outperformed expectations, with cumulative deliveries reaching 1.34 million by the end of June.
The recent slowdown in deliveries and heightened competitive pressures coincide with the market entry of more affordable electric SUVs, notably Xiaomi&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/XIACY#OTC">XIACY</a>) YU7. This has intensified pricing and market share battles across China&#8217;s dynamic EV landscape, impacting established players like Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Li Auto alike.
Price Action: LI stock is trading lower by 5.75% to $27.50 at&nbsp;last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/07/46687494/on-semiconductor-jumps-after-nvidia-deal-is-this-the-next-big-ai-power-play" target="_blank" rel="noreferrer noopener">ON Semiconductor Jumps After Nvidia Deal—Is This The Next Big AI Power Play?</a></li>
</ul>
Photo by Robert Way via Shutterstock

News

Movers

Tech

NVDA

TSLA

XIACY

Li Auto Debuts Li i8 Electric SUV With Ultra-Fast Charging

<a href="https://www.bloomberg.com/news/articles/2025-07-29/nasdaq-nordic-cancels-some-trades-following-technical-glitch" title="https://www.bloomberg.com/news/articles/2025-07-29/nasdaq-nordic-cancels-some-trades-following-technical-glitch">https://www.bloomberg.com/news/articles/2025-07-29/nasdaq-nordic-cancels-some-trades-following-technical-glitch</a>

NDAQ

'Nasdaq Nordic Cancels Some Trades Following Technical Glitch' - Bloomberg News

<a href="https://www.bloomberg.com/news/articles/2025-07-29/apple-loses-ai-models-engineer-bowen-zhang-to-meta-superintelligence-team" title="https://www.bloomberg.com/news/articles/2025-07-29/apple-loses-ai-models-engineer-bowen-zhang-to-meta-superintelligence-team">https://www.bloomberg.com/news/articles/2025-07-29/apple-loses-ai-models-engineer-bowen-zhang-to-meta-superintelligence-team</a>

Management

AAPL

'Apple Loses Fourth AI Researcher in a Month to Meta's Superintelligence Team' - Bloomberg News

<h3>Gainers</h3>
<ul>
<li>Super X AI Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUPX#NASDAQ">SUPX</a>) stock increased by 33.9% to $15.21 during Tuesday's regular session. The market value of their outstanding shares is at $223.4 million. </li>
<li>Newegg Commerce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEGG#NASDAQ">NEGG</a>) shares rose 24.75% to $48.75. The company's market cap stands at $761.2 million. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock rose 15.42% to $2.17. The market value of their outstanding shares is at $26.0 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares moved upwards by 14.22% to $1.25. The market value of their outstanding shares is at $318.4 million. </li>
<li>Polaris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PII#NYSE">PII</a>) shares rose 13.29% to $56.06. The market value of their outstanding shares is at $2.7 billion. The company's, Q2 earnings came out today. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares increased by 12.62% to $4.37. The market value of their outstanding shares is at $31.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) stock fell 51.1% to $0.06 during Tuesday's regular session. The company's market cap stands at $5.9 million. </li>
<li>Leslies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) stock fell 33.93% to $0.43. The market value of their outstanding shares is at $119.4 million. </li>
<li>Connexa Sports Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYAI#NASDAQ">YYAI</a>) stock decreased by 25.24% to $3.21. The market value of their outstanding shares is at $62.6 million. </li>
<li>YSX Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YSXT#NASDAQ">YSXT</a>) shares fell 20.0% to $2.92. The company's market cap stands at $85.5 million. </li>
<li>Classover Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIDZ#NASDAQ">KIDZ</a>) shares declined by 17.68% to $1.65. The market value of their outstanding shares is at $49.1 million. </li>
<li>Solid Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDP#NASDAQ">SLDP</a>) shares decreased by 17.41% to $3.35. The company's market cap stands at $726.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

KIDZ

LESL

NEGG

NWTN

QVCGA

SLDP

SUPX

YSXT

Connexa Sports Technologies Inc. - Common Stock

YYAI

12 Consumer Discretionary Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) stock moved upwards by 238.3% to $1.87 during Tuesday's regular session. The market value of their outstanding shares is at $17.1 million. </li>
<li>Salarius Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) shares increased by 59.3% to $1.18. The market value of their outstanding shares is at $1.5 million. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares rose 29.03% to $0.71. The company's market cap stands at $18.9 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares rose 25.74% to $0.69. The market value of their outstanding shares is at $16.6 million. </li>
<li>Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) shares increased by 19.73% to $16.59. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Exagen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XGN#NASDAQ">XGN</a>) shares rose 16.91% to $8.64. The company's market cap stands at $161.5 million. As per the news, the Q2 earnings report came out today. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares fell 53.8% to $3.33 during Tuesday's regular session. The company's market cap stands at $5.5 million. </li>
<li>Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) stock fell 26.05% to $3.35. The market value of their outstanding shares is at $10.7 million. The company's, Q2 earnings came out yesterday. </li>
<li>NeoGenomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) shares declined by 24.77% to $4.86. The market value of their outstanding shares is at $831.3 million. As per the press release, Q2 earnings came out today. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock fell 21.96% to $0.35. The company's market cap stands at $18.4 million. </li>
<li>Sonnet BioTherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONN#NASDAQ">SONN</a>) shares decreased by 21.42% to $3.18. The market value of their outstanding shares is at $25.3 million. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAKA#NASDAQ">NAKA</a>) shares declined by 21.35% to $8.33. The company's market cap stands at $80.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CLDI

DRRX

EKSO

MBRX

NAKA

PRPH

SLRX

SONN

SRPT

12 Health Care Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>Rich Sparkle Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANPA#NASDAQ">ANPA</a>) stock increased by 39.5% to $36.29 during Tuesday's regular session. The market value of their outstanding shares is at $325.1 million. </li>
<li>CECO Environmental (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CECO#NASDAQ">CECO</a>) stock increased by 16.39% to $40.4. The market value of their outstanding shares is at $1.2 billion. The company's, Q2 earnings came out today. </li>
<li>Chart Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GTLS#NYSE">GTLS</a>) stock increased by 15.5% to $198.27. The company's market cap stands at $7.3 billion. As per the news, the Q2 earnings report came out today. </li>
<li>Founder Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) shares rose 14.77% to $1.16. The market value of their outstanding shares is at $19.6 million. </li>
<li>Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) shares rose 12.84% to $1.93. The market value of their outstanding shares is at $3.2 million. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) shares increased by 10.46% to $3.59. The market value of their outstanding shares is at $162.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>VisionWave Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VWAV#NASDAQ">VWAV</a>) stock fell 33.2% to $7.35 during Tuesday's regular session. The market value of their outstanding shares is at $156.9 million. </li>
<li>CEA Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VAPE#NASDAQ">VAPE</a>) stock decreased by 30.37% to $40.1. The company's market cap stands at $48.4 million. </li>
<li>WANG &amp; LEE Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLGS#NASDAQ">WLGS</a>) stock declined by 29.56% to $0.06. The company's market cap stands at $2.6 million. </li>
<li>FiscalNote Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) shares declined by 27.57% to $0.57. The market value of their outstanding shares is at $124.8 million. </li>
<li>Graphjet Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTI#NASDAQ">GTI</a>) shares declined by 19.87% to $0.11. The company's market cap stands at $21.1 million. </li>
<li>Stem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STEM#NYSE">STEM</a>) shares decreased by 18.41% to $15.43. The market value of their outstanding shares is at $157.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ANPA

CECO

ELPW

GTLS

NOTE

SOAR

STEM

VAPE

VWAV

WLGS

12 Industrials Stocks Moving In Tuesday's Intraday Session

<h3>Gainers</h3>
<ul>
<li>ScanTech AI Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STAI#NASDAQ">STAI</a>) stock rose 86.9% to $1.25 during Tuesday's regular session. The company's market cap stands at $13.8 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) stock rose 20.88% to $118.88. The market value of their outstanding shares is at $5.2 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>CommVault Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVLT#NASDAQ">CVLT</a>) stock moved upwards by 18.83% to $194.22. The company's market cap stands at $7.2 billion. As per the press release, Q1 earnings came out today. </li>
<li>Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) stock increased by 17.96% to $25.05. The market value of their outstanding shares is at $5.2 billion. As per the press release, Q2 earnings came out yesterday. </li>
<li>Mega Fortune Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGRT#NASDAQ">MGRT</a>) shares increased by 17.92% to $2.69. The market value of their outstanding shares is at $31.3 million. </li>
<li>Acorn Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACFN#NASDAQ">ACFN</a>) stock moved upwards by 16.15% to $25.5. The company's market cap stands at $54.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Global Engine Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLE#NASDAQ">GLE</a>) shares fell 46.6% to $1.58 during Tuesday's regular session. The market value of their outstanding shares is at $54.3 million. </li>
<li>SMX (Security Matters) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMX#NASDAQ">SMX</a>) shares decreased by 25.8% to $1.61. The company's market cap stands at $8.2 million. </li>
<li>Robot Consulting Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAWR#NASDAQ">LAWR</a>) stock fell 19.64% to $2.25. The market value of their outstanding shares is at $128.6 million. </li>
<li>Soluna Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNHP#NASDAQ">SLNHP</a>) stock declined by 19.56% to $3.44. The company's market cap stands at $3.0 million. </li>
<li>MicroAlgo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares decreased by 15.42% to $9.86. The market value of their outstanding shares is at $127.5 million. </li>
<li>Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) stock fell 14.7% to $2.09. The market value of their outstanding shares is at $249.5 million. As per the news, the Q2 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACFN

AMKR

CVLT

LAWR

MGRT

MLGO

PERF

SANM

SLNHP

STAI

12 Information Technology Stocks Moving In Tuesday's Intraday Session

Rumors

Trading Ideas

AXGN

Watching Axogen; Shares Spike Higher, Traders Circulate Unconfirmed Rumor Co Is Exploring Sale

WIIM

Woodward shares are trading higher after UBS raised its price target on the stock from $283 to $299.

Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is expected to highlight growth from AI and cloud services when the technology giant reports its fourth-quarter financial results on Wednesday <a href="https://www.benzinga.com/earnings">after the market close.</a>
Here are the earnings estimates, what experts are saying, and key items to watch.
Earnings Estimates: Analysts expect Microsoft to report fourth-quarter revenue of $73.8 billion. That&#8217;s up from $64.7 billion in last year's fourth quarter, according to data<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0729"> from Benzinga Pro.</a>
The company has beaten analyst estimates for revenue in nine straight quarters.
Analysts expect Microsoft to report fourth-quarter earnings per share of $3.37, up from $2.95 in last year's fourth quarter. The company has beaten analyst estimates for earnings per share in 11 straight quarters.
Read Also: <a href="https://www.benzinga.com/markets/earnings/25/07/46693997/wall-street-earnings-preview-microsoft-apple-meta-amazon-mastercard-visa">$19.5 Trillion Earnings Blitz: Wall Street Faces Make-Or-Break 72 Hours</a>
What Experts Are Saying: Microsoft has been a standout tech stock in 2025. Its shares are up 22% year-to-date and trading at all-time highs, as highlighted by Freedom Capital Markets Chief Global Strategist Jay Woods.
"The question is—can they keep the momentum going?" Woods asks in a weekly <a href="https://jaywoods.substack.com/">newsletter</a>.
Woods expects investors to ask how Microsoft is integrating its AI spending into products and whether it's boosting revenue.
Another key focus is Microsoft&#8217;s cloud services performance, Woods says, noting how Azure will &#8220;bolster&#8221; cloud operations.
Wedbush analyst Dan Ives <a href="https://www.benzinga.com/markets/equities/25/07/46627073/dan-ives-calls-microsoft-scottie-scheffler-of-software-ahead-of-earnings-says-satya-nadella-led-cloud-giant-is-firing-on-all-cylinders-in-ai-boom">reiterated an Outperform rating</a> and $600 price target ahead of Microsoft's quarterly results.
"We expect more good news next week from Redmond as Nadella &amp; Co. will deliver another robust quarter driven by the AI Revolution," Ives said in a recent analyst note.
Ives said Microsoft is "firing on all cylinders" ahead of the earnings report.
In his latest note, Ives said the $600 price target could be "conservative.&#8221; Microsoft will be the next company to join the $4 trillion market capitalization club this summer and possibly hit $5 trillion in the next 18 months, he predicts.
Here are some other recent <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">analyst ratings on Microsoft </a>and their price targets:
<ul class="wp-block-list">
<li>Raymond James: Maintained Outperform rating, raised price target from $490 to $570</li>
<li>Stifel: Maintained Buy rating, raised price target from $500 to $550</li>
<li>Evercore ISI Group: Maintained Outperform rating, raised price target from $515 to $545</li>
<li>Loop Capital: Maintained Buy rating, raised price target from $550 to $600</li>
<li>UBS: Maintained Buy rating, raised price target from $500 to $600</li>
</ul>
Key Items to Watch: Microsoft's earnings report comes as the <a href="https://www.benzinga.com/markets/tech/25/07/46647734/microsoft-probes-possible-breach-of-its-cyber-threat-notification-system-after-suspected-chinese-hack-report">company is investigating </a>whether a leak from its early alert system for cybersecurity companies may have contributed to hackers being able to exploit flaws in the SharePoint service.
The company may provide an update on the cybersecurity item and the potential financial ramifications of the hack.
Investors and analysts will likely center on AI and cloud when Microsoft reports results and management share commentary on the results and future guidance. Microsoft saw growth across its main segments in<a href="https://www.benzinga.com/25/04/45117886/microsoft-q3-earnings-highlights-revenue-beat-eps-beat-cloud-revenue-up-20"> the third quarter</a> with Intelligent Cloud revenue up 21% year-over-year, the most of any main segment.
Overall cloud revenue is up 20% year-over-year. 
&#8220;Cloud and AI are the essential inputs for every business to expand output, reduce costs, and accelerate growth,&#8221; Microsoft CEO&nbsp;Satya Nadella&nbsp;said at the time. &#8220;From AI infra and platforms to apps, we are innovating across the stack to deliver for our customers.&#8221;
Microsoft's earnings report could have a huge impact on some of the largest stock market indexes and ETFs. The stock is a member of the S&amp;P 500, Dow Jones Industrial Average and Magnificent 7.
With its high stock price, Microsoft is the second largest weighting (7.0%) in the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), which tracks the price-weighted Dow Jones Industrial Average.
Microsoft is also the second-largest holding in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 at 7.0% of assets.
In the Roundhill Magnificent Seven ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MAGS#BATS">MAGS</a>), Microsoft is the fifth-largest holding at 13.9% of assets.
Microsoft is one of several Magnificent 7 stocks that will report during the week and could be one of the most important stocks given its prominence in these key indexes along with its presence among key growth sectors like AI and cloud. <a href="https://www.benzinga.com/go/robinhood-retirement" target="_blank" rel="noreferrer noopener"></a>
MSFT Price Action: Microsoft stock is up 0.3% to $514.04 on Tuesday versus a 52-week trading range of $344.79 to $518.29. Microsoft stock is up 22.8% year-to-date, outperforming the S&amp;P 500 (+8.8%) and Dow Jones Industrial Average (+5.3%).
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/25/06/45973429/trump-wants-babies-to-get-1000-to-invest-at-birth-this-maginicent-7-stock-tops-poll-for-18-year-growth">Trump Wants Babies To Get $1,000 To Invest At Birth: This Magnificent 7 Stock Tops Poll For 18-Year Growth</a></li>
</ul>
Image: Shutterstock

Analyst Color

Previews

Analyst Ratings

SPDR Dow Jones Industrial Average ETF Trust

MAGS

MSFT

Microsoft Q4 Preview: Can The Tech Giant Beat Forecasts For 10th Straight Quarter?

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock is trading lower on Tuesday after its weight loss drug rival, Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), trimmed its 2025 financial outlook.
The cut marks the&nbsp;<a target="_blank" href="https://www.benzinga.com/25/05/45252150/novo-nordisk-expects-fda-decision-for-oral-wegovy-by-end-of-2025-reports-mixed-q1-earnings" rel="noreferrer noopener">second time this year</a> Novo Nordisk has lowered its guidance.
Novo Nordisk now projects 2025 sales growth to be 8-14% at constant exchange rates, a notable reduction from its earlier forecast of 13-21%.
Similarly, the outlook for operating profit growth has been lowered to 10-16% from the previously anticipated 16-24%.
This revised guidance largely stems from a slower-than-expected penetration of its branded GLP-1 treatments, particularly in the United States, a market increasingly impacted by the persistent use of <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46685132/ozempic-and-wegovy-maker-cuts-outlook-in-surprise-move-picks-new-ceo" rel="noreferrer noopener">compounded GLP-1 alternatives</a>.
<h2 class="wp-block-heading">GLP-1 Drugs</h2>
In a letter to the U.S. Food and Drug Administration (FDA) Commissioner&nbsp;Marty Makary on Friday, over 80 bipartisan members asked the&nbsp;agency to stop counterfeit and copycat versions of GLP-1 drugs like&nbsp;Novo Nordisk&#8217;s Wegovy (semaglutide) and&nbsp;Eli Lilly&#8217;s Zepbound&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">from flooding the market</a>.
The group wrote&nbsp;the letter urging immediate action against the rising threat of illegal, counterfeit anti-obesity medications entering the U.S.&nbsp;
The group urged the FDA to issue warning letters, pursue civil enforcement, and monitor non-compliant online retailers and compounding pharmacies selling <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46641326/congress-sounds-alarm-over-illegal-weight-loss-drug-imports-from-china" rel="noreferrer noopener">unapproved weight-loss drugs</a>.
In April, after media reports on Hims &amp; Hers Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) partnering with the company, Eli Lilly said in a statement that it has no affiliation with Hims &amp; Hers.
Zepbound (tirzepatide) can be prescribed by any licensed healthcare professional. People who are commercially insured with coverage for&nbsp;Zepbound&nbsp;may be eligible to pay as little as&nbsp;$25.
<h2 class="wp-block-heading">Trial Data</h2>
On Tuesday, Eli Lilly also released topline results from the Phase 3 BRUIN CLL-314 trial of Jaypirca (pirtobrutinib) versus Imbruvica (ibrutinib) in patients with chronic lymphocytic leukemia or <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46682559/lillys-jaypirca-pirtobrutinib-the-first-and-only-approved-non-covalent-reversible-btk-inhibitor-me" rel="noreferrer noopener">small lymphocytic lymphoma (CLL/SLL)</a>.
Johnson &amp; Johnson&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) Imbruvica is a covalent BTK inhibitor.
The study enrolled patients with treatment-naïve CLL/SLL and those previously treated but were BTK inhibitor-naïve.
The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations.
ORR favored pirtobrutinib with a nominal P-value for superiority&nbsp;(p &lt;0.05). Progression-free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending toward pirtobrutinib.
BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients.
The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025.
These data build on the previously reported positive results from the BRUIN Phase 1/2 trial and the Phase 3 BRUIN CLL-321 trial, the first randomized, controlled study ever conducted in an exclusively post-covalent BTK inhibitor population.
The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally.
Price Action: LLY stock is down 4.93% at $768.27 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46687653/sofi-technologies-stock-surges-on-exceptional-q2-earnings-raised-guidance" target="_blank" rel="noreferrer noopener">SoFi Technologies Stock Surges On &#8216;Exceptional&#8217; Q2 Earnings, Raised Guidance</a></li>
</ul>
Image Via Shutterstock

Biotech

Large Cap

Health Care

General

Hims & Hers Health, Inc. Class A Common Stock

HIMS

What's Going On With Eli Lilly Stock On Tuesday?

Hartford Insurance Group shares are trading higher. JP Morgan raised its price target on the stock from $140 to $142.

Global Engine Group Shares Halted On Circuit Breaker To The Downside, Stock Now Down -39.4%

Silgan Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLGN#NYSE">SLGN</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Silgan Hldgs will report an earnings per share (EPS) of $1.03.
The announcement from Silgan Hldgs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.03, which was followed by a 2.05% increase in the share price the next day.
Here's a look at Silgan Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.79</td>
<td>0.82</td>
<td>1.24</td>
<td>0.86</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.82</td>
<td>0.85</td>
<td>1.21</td>
<td>0.88</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808592_0.png" alt="eps graph" />
<h3>Market Performance of Silgan Hldgs's Stock</h3>
Shares of Silgan Hldgs were trading at $55.47 as of July 28. Over the last 52-week period, shares are up 7.73%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<h3>Analyst Insights on Silgan Hldgs</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Silgan Hldgs.
A total of 6 analyst ratings have been received for Silgan Hldgs, with the consensus rating being Buy. The average one-year price target stands at $62.0, suggesting a potential 11.77% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of and Greif, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Greif, with an average 1-year price target of $72.0, suggesting a potential 29.8% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for and Greif, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Silgan Hldgs</td>
<td>Buy</td>
<td>11.36%</td>
<td>$270.40M</td>
<td>3.34%</td>
</tr>
<tr>
<td>Greif</td>
<td>Outperform</td>
<td>1.07%</td>
<td>$319.50M</td>
<td>2.27%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Silgan Hldgs has higher revenue growth compared to its peer. Silgan Hldgs has lower gross profit than its peer. Silgan Hldgs has higher return on equity than its peer.
<h3>Get to Know Silgan Hldgs Better</h3>
Silgan Holdings manufactures about half of the metal food containers in North America. Its major customers include Campbell Soup, Nestle, and Del Monte. Silgan's other business segments include plastic dispensers and containers for personal and healthcare products and a closures business that manufactures metal and plastic lids and caps.
<h3>Breaking Down Silgan Hldgs's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Silgan Hldgs showcased positive performance, achieving a revenue growth rate of 11.36% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Silgan Hldgs's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.63% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Silgan Hldgs's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Silgan Hldgs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.78%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Silgan Hldgs's debt-to-equity ratio stands notably higher than the industry average, reaching 2.22. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/SLGN/earnings">To track all earnings releases for Silgan Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

SLGN

Silgan Hldgs's Earnings: A Preview

Roth Capital analyst Philip Shen reiterates Quanta Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>) with a Buy and raises the price target from $350 to $450.

Price Target

Reiteration

Roth Capital Reiterates Buy on Quanta Services, Raises Price Target to $450

Scotts Miracle Gro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMG#NYSE">SMG</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement.
Analysts estimate that Scotts Miracle Gro will report an earnings per share (EPS) of $2.23. 
The market awaits Scotts Miracle Gro's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.05, leading to a 5.92% increase in the share price on the subsequent day.
Here's a look at Scotts Miracle Gro's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.93</td>
<td>-1.23</td>
<td>-1.95</td>
<td>1.93</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.98</td>
<td>-0.89</td>
<td>-2.31</td>
<td>2.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>6.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808583_0.png" alt="eps graph" />
<h3>Tracking Scotts Miracle Gro's Stock Performance</h3>
Shares of Scotts Miracle Gro were trading at $69.16 as of July 28. Over the last 52-week period, shares are down 13.93%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/SMG/earnings">To track all earnings releases for Scotts Miracle Gro visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Scotts Miracle Gro's Earnings Forecast

Silicon Motion Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIMO#NASDAQ">SIMO</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Silicon Motion Technology will report an earnings per share (EPS) of $0.50.
The market awaits Silicon Motion Technology's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.15, leading to a 9.61% increase in the share price on the subsequent day.
Here's a look at Silicon Motion Technology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.45</td>
<td>0.84</td>
<td>0.85</td>
<td>0.94</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.60</td>
<td>0.91</td>
<td>0.92</td>
<td>0.96</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-2.0%</td>
<td>-4.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808574_0.png" alt="eps graph" />
<h3>Silicon Motion Technology Share Price Analysis</h3>
Shares of Silicon Motion Technology were trading at $75.79 as of July 28. Over the last 52-week period, shares are up 10.25%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/SIMO/earnings">To track all earnings releases for Silicon Motion Technology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SIMO

A Look Ahead: Silicon Motion Technology's Earnings Forecast

NorthWestern (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWE#NASDAQ">NWE</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release.
Analysts are estimating that NorthWestern will report an earnings per share (EPS) of $0.38.
The market awaits NorthWestern's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.04 in the last quarter, leading to a 2.15% drop in the share price on the following day.
Here's a look at NorthWestern's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.18</td>
<td>1.13</td>
<td>0.68</td>
<td>0.52</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.22</td>
<td>1.13</td>
<td>0.65</td>
<td>0.53</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>-2.0%</td>
<td>-3.0%</td>
<td>0.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808563_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of NorthWestern were trading at $52.11 as of July 28. Over the last 52-week period, shares are down 2.34%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on NorthWestern</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on NorthWestern.
With 3 analyst ratings, NorthWestern has a consensus rating of Neutral. The average one-year price target is $60.0, indicating a potential 15.14% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Black Hills, NiSource and CMS Energy, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Black Hills, with an average 1-year price target of $68.0, suggesting a potential 30.49% upside.</li>
<li>Analysts currently favor an Buy trajectory for NiSource, with an average 1-year price target of $44.0, suggesting a potential 15.56% downside.</li>
<li>Analysts currently favor an Neutral trajectory for CMS Energy, with an average 1-year price target of $74.5, suggesting a potential 42.97% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary offers a detailed examination of key metrics for Black Hills, NiSource and CMS Energy, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>NorthWestern Energy Group</td>
<td>Neutral</td>
<td>-1.83%</td>
<td>$271.72M</td>
<td>2.67%</td>
</tr>
<tr>
<td>Black Hills</td>
<td>Outperform</td>
<td>10.85%</td>
<td>$291.80M</td>
<td>3.76%</td>
</tr>
<tr>
<td>NiSource</td>
<td>Buy</td>
<td>27.95%</td>
<td>$1.11B</td>
<td>5.40%</td>
</tr>
<tr>
<td>CMS Energy</td>
<td>Neutral</td>
<td>12.45%</td>
<td>$1.04B</td>
<td>3.75%</td>
</tr>
</tbody>
</table>

Key Takeaway:
NorthWestern ranks at the bottom for Revenue Growth with a negative percentage. It is also at the bottom for Gross Profit. For Return on Equity, NorthWestern is at the bottom as well.
<h3>Get to Know NorthWestern Better</h3>
NorthWestern Energy Group Inc provides electricity and natural gas services in the Upper Midwest and Northwest of the U.S. in the states of Montana, South Dakota, Nebraska, and Yellowstone National Park. The company's primary segments include Electric utility operations, which include the generation, purchase, transmission, and distribution of electricity, and Natural Gas utility operations, which include the production, purchase, transmission, storage, and distribution of natural gas. The company uses thermal, wind, hydro, or renewable energy in varying quantities, depending on the location of the facilities, to generate power. The company derives the majority of its revenue from the Electric utility operations segment.
<h3>NorthWestern's Financial Performance</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining NorthWestern's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -1.83% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Utilities sector.
Net Margin: NorthWestern's net margin is impressive, surpassing industry averages. With a net margin of 16.49%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): NorthWestern's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.67%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): NorthWestern's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of 0.96%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 1.08, NorthWestern adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/NWE/earnings">To track all earnings releases for NorthWestern visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of NorthWestern's Earnings

Teva Pharmaceutical Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-07-30. Here's what investors need to know before the announcement.
Analysts estimate that Teva Pharmaceutical Indus will report an earnings per share (EPS) of $0.61. 
The market awaits Teva Pharmaceutical Indus's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 2.67% increase in the share price on the subsequent day.
Here's a look at Teva Pharmaceutical Indus's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.46</td>
<td>0.70</td>
<td>0.66</td>
<td>0.55</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.52</td>
<td>0.71</td>
<td>0.69</td>
<td>0.61</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-4.0%</td>
<td>0.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808549_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Teva Pharmaceutical Indus were trading at $16.51 as of July 28. Over the last 52-week period, shares are down 5.74%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Teva Pharmaceutical Indus</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Teva Pharmaceutical Indus.
A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The average one-year price target stands at $23.4, suggesting a potential 41.73% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Viatris, Corcept Therapeutics and Elanco Animal Health, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Neutral trajectory for Viatris, with an average 1-year price target of $10.0, suggesting a potential 39.43% downside.</li>
<li>Analysts currently favor an Buy trajectory for Corcept Therapeutics, with an average 1-year price target of $145.0, suggesting a potential 778.26% upside.</li>
<li>Analysts currently favor an Buy trajectory for Elanco Animal Health, with an average 1-year price target of $16.8, suggesting a potential 1.76% upside.</li>
</ul>
<h3>Peer Analysis Summary</h3>
The peer analysis summary provides a snapshot of key metrics for Viatris, Corcept Therapeutics and Elanco Animal Health, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Teva Pharmaceutical Indus</td>
<td>Buy</td>
<td>1.89%</td>
<td>$1.88B</td>
<td>3.68%</td>
</tr>
<tr>
<td>Viatris</td>
<td>Neutral</td>
<td>-11.17%</td>
<td>$1.16B</td>
<td>-17.74%</td>
</tr>
<tr>
<td>Corcept Therapeutics</td>
<td>Buy</td>
<td>7.09%</td>
<td>$154.81M</td>
<td>2.98%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Buy</td>
<td>-1.00%</td>
<td>$684M</td>
<td>1.08%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Teva Pharmaceutical Indus ranks highest in Revenue Growth among its peers. It also leads in Gross Profit. However, it ranks lowest in Return on Equity.
<h3>Delving into Teva Pharmaceutical Indus's Background</h3>
Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
<h3>Teva Pharmaceutical Indus's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Teva Pharmaceutical Indus's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 1.89%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Teva Pharmaceutical Indus's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 5.5%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.68%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.55%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Teva Pharmaceutical Indus's debt-to-equity ratio surpasses industry norms, standing at 2.71. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<a href="https://www.benzinga.com/quote/TEVA/earnings">To track all earnings releases for Teva Pharmaceutical Indus visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TEVA

A Glimpse of Teva Pharmaceutical Indus's Earnings Potential

Penske Automotive Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAG#NYSE">PAG</a>) is preparing to release its quarterly earnings on Wednesday, 2025-07-30. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Penske Automotive Group to report an earnings per share (EPS) of $3.56.
Investors in Penske Automotive Group are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings History Snapshot</h3>
Last quarter the company beat EPS by $0.11, which was followed by a 0.04% drop in the share price the next day.
Here's a look at Penske Automotive Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>3.28</td>
<td>3.29</td>
<td>3.41</td>
<td>3.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>3.39</td>
<td>3.54</td>
<td>3.39</td>
<td>3.61</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753808530_0.png" alt="eps graph" />
<h3>Tracking Penske Automotive Group's Stock Performance</h3>
Shares of Penske Automotive Group were trading at $170.25 as of July 28. Over the last 52-week period, shares are down 4.03%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<h3>Analyst Observations about Penske Automotive Group</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Penske Automotive Group.
The consensus rating for Penske Automotive Group is Buy, based on 5 analyst ratings. With an average one-year price target of $167.0, there's a potential 1.91% downside.
<h3>Analyzing Ratings Among Peers</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of CarMax, Murphy USA and Lithia Motors, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for CarMax, with an average 1-year price target of $82.9, suggesting a potential 51.31% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Murphy USA, with an average 1-year price target of $493.33, suggesting a potential 189.77% upside.</li>
<li>Analysts currently favor an Buy trajectory for Lithia Motors, with an average 1-year price target of $399.67, suggesting a potential 134.75% upside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
The peer analysis summary provides a snapshot of key metrics for CarMax, Murphy USA and Lithia Motors, illuminating their respective standings within the industry. These metrics offer valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Penske Automotive Group</td>
<td>Buy</td>
<td>2.10%</td>
<td>$1.27B</td>
<td>4.61%</td>
</tr>
<tr>
<td>CarMax</td>
<td>Outperform</td>
<td>6.09%</td>
<td>$893.62M</td>
<td>3.36%</td>
</tr>
<tr>
<td>Murphy USA</td>
<td>Outperform</td>
<td>-6.57%</td>
<td>$483.60M</td>
<td>6.82%</td>
</tr>
<tr>
<td>Lithia Motors</td>
<td>Buy</td>
<td>7.20%</td>
<td>$1.41B</td>
<td>3.12%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Penske Automotive Group ranks at the top for Revenue Growth and Gross Profit among its peers. It is in the middle for Consensus rating and Return on Equity.
<h3>Get to Know Penske Automotive Group Better</h3>
Penske Automotive Group operates in 19 US states and overseas. It has over 150 US and Puerto Rico light-vehicle stores as well as 210 franchised dealerships overseas, primarily in the United Kingdom but also in Australia, Germany, Italy, and Japan. The company is the third-largest US publicly traded dealership in terms of light-vehicle revenue and sells more than 40 brands, with over 90% of retail automotive revenue coming from luxury and import names. Other segments are service and finance and insurance. The firm's Premier Truck Group owns 45 truck dealerships selling mostly Freightliner and Western Star brands, and Penske owns 16 used-vehicle stores, mostly in the US and UK under the CarShop (US) and Sytner Select (UK) brands. Penske is based in Bloomfield Hills, Michigan.
<h3>Penske Automotive Group's Financial Performance</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Penske Automotive Group's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 2.1%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Penske Automotive Group's net margin excels beyond industry benchmarks, reaching 3.21%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.61%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.45%, the company showcases effective utilization of assets.
Debt Management: Penske Automotive Group's debt-to-equity ratio is below the industry average. With a ratio of 1.5, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/PAG/earnings">To track all earnings releases for Penske Automotive Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Penske Automotive Group's Earnings

Cdon

Comments

Cdon

Notizie

Ultime notizie per Cdon (OTC:CDOAF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO